Cytokinetics Ownership | Who Owns Cytokinetics?
Cytokinetics Ownership Summary
Cytokinetics is owned by 43.15% institutional investors, 0.70% insiders, and 56.15% retail investors. Blackrock is the largest institutional shareholder, holding 14.40% of CYTK shares. T. Rowe Price Capital Appreciation is the top mutual fund, with 3.76% of its assets in Cytokinetics shares.
CYTK Ownership Benchmark
| Type | Name | % Inst | % Insiders | % Retail |
|---|---|---|---|---|
| Stock | Cytokinetics | 43.15% | 0.70% | 56.15% |
| Sector | Healthcare Stocks | 35.78% | 11.87% | 52.36% |
| Industry | Biotech Stocks | 36.05% | 11.82% | 52.13% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
| Holder | Shares | % Holding | Value |
|---|---|---|---|
| Blackrock | 14.67M | 14.40% | $794.97M |
| T. rowe price investment management | 17.52M | 14.36% | $1.15B |
| Blackrock funding, inc. /de | 16.55M | 13.56% | $1.09B |
| Vanguard group | 12.05M | 10.04% | $765.54M |
| Fmr | 10.72M | 8.79% | $706.76M |
| Wellington management group llp | 8.01M | 6.56% | $527.91M |
| Tudor investment corp et al | 6.00M | 5.02% | $6.86M |
| State street | 5.75M | 4.71% | $378.67M |
| Avoro capital advisors | 3.33M | 2.73% | $219.70M |
| Geode capital management | 3.22M | 2.64% | $211.97M |
Top Institutional Shareholders by % of Total Assets
| Holder | Shares | % Assets | Value |
|---|---|---|---|
| Rp management | 980.39K | 22.73% | $51.76M |
| Foresite capital management iv | 503.30K | 13.99% | $33.17M |
| Sarissa capital management lp | 228.62K | 9.56% | $15.07M |
| Boxer capital | 2.10M | 5.99% | $113.78M |
| Melqart asset management (uk) | 843.95K | 5.48% | $55.62M |
| Integral health asset management | 1.60M | 5.04% | $105.46M |
| Checkpoint capital | 180.00K | 4.26% | $11.86M |
| Gsk | 340.43K | 3.75% | $22.44M |
| Nationale-nederlanden powszechne towarzystwo emerytalne | 660.31K | 3.69% | $43.52M |
| Monashee investment management | 100.00K | 3.59% | $6.59M |
Top Buyers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Tudor investment corp et al | 6.00M | 0.01% | 6.00M |
| Avoro capital advisors | 3.33M | 2.16% | 3.33M |
| Blackrock | 14.67M | 0.02% | 2.26M |
| Paradigm biocapital advisors lp | 1.48M | 1.99% | 1.48M |
| William blair investment management | 1.09M | 0.24% | 1.09M |
Top Sellers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Darwin global management | - | - | -4.58M |
| Fmr | 10.72M | 0.04% | -2.08M |
| Deep track capital, lp | 1.37M | 1.48% | -1.96M |
| Pfm health sciences, lp | - | - | -1.76M |
| Westfield capital management co lp | - | - | -1.31M |
New Positions
| Holder | Shares | % Assets | Change | Value |
|---|---|---|---|---|
| Tudor investment corp et al | 6.00M | 0.01% | 6.00M | $6.86M |
| Avoro capital advisors | 3.33M | 2.16% | 3.33M | $219.70M |
| Paradigm biocapital advisors lp | 1.48M | 1.99% | 1.48M | $97.60M |
| William blair investment management | 1.09M | 0.24% | 1.09M | $71.68M |
| Balyasny asset management | 992.54K | 0.08% | 992.54K | $65.42M |
Sold Out
| Holder | Change |
|---|---|
| New england capital financial advisors | -1.00 |
| Strategic advocates | -2.00 |
| Financial gravity asset management | -2.00 |
| Td private client wealth | -2.00 |
| Ross\johnson & associates | -2.00 |
Institutional Ownership Trends
| Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 31, 2026 | 258 | -45.45% | 51,788,965 | -62.86% | 43 | 0.32% | 147 | -42.35% | 69 | -46.92% |
| Dec 31, 2025 | 328 | -22.64% | 72,535,010 | -48.66% | 60 | 0.43% | 182 | -19.82% | 87 | -18.69% |
| Sep 30, 2025 | 403 | 16.47% | 144,458,231 | 4.66% | 120 | 0.91% | 217 | 25.43% | 105 | -0.94% |
| Jun 30, 2025 | 344 | -10.88% | 137,969,518 | 1.88% | 115 | 0.88% | 171 | -14.50% | 106 | -0.93% |
| Mar 31, 2025 | 25 | -93.40% | 16,158,180 | -87.73% | 13 | 0.11% | 15 | -91.28% | 5 | -96.09% |
Top Mutual Funds Shareholders
| Holder | Shares | % Holding | Change |
|---|---|---|---|
| T. Rowe Price Capital Appreciation | 5.11M | 3.76% | - |
| Vanguard Health Care Inv | 4.06M | 3.31% | 14.10K |
| iShares Core S&P Mid-Cap ETF | 4.48M | 3.30% | 840.00 |
| Vanguard Total Stock Mkt Idx Inv | 3.93M | 3.16% | 22.81K |
| Vanguard US Total Market Shares ETF | 3.75M | 3.15% | 128.42K |
| Vanguard Small Cap Index | 2.84M | 2.28% | -5.96K |
| iShares Russell 2000 ETF | 3.10M | 2.28% | 28.60K |
| SPDR® S&P Biotech ETF | 2.07M | 1.73% | 4.61K |
| American Funds SMALLCAP World A | 2.11M | 1.72% | 936.12K |
| Fidelity OTC | 2.27M | 1.67% | - |
Recent Insider Transactions
| Date | Name | Role | Activity | Value |
|---|---|---|---|---|
| Jul 01, 2026 | Blum Robert I | President & CEO | Sell | $636.90K |
| Jul 01, 2026 | Callos Andrew | EVP, Chief Commercial Officer | Sell | $1.29M |
| Jul 01, 2026 | Lee Sung | EVP, Chief Financial Officer | Sell | $97.62K |
| Jun 24, 2026 | Lee Sung | EVP, Chief Financial Officer | Sell | $3.19M |
| Jun 29, 2026 | Lee Sung | EVP, Chief Financial Officer | Sell | $266.39K |
Insider Transactions Trends
| Date | Buy | Sell |
|---|---|---|
| 2026 Q3 | - | 3 |
| 2026 Q2 | - | 25 |
| 2026 Q1 | - | 22 |
| 2025 Q4 | - | 20 |
| 2025 Q3 | - | 15 |
CYTK Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools